Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Diamyd Medical and the Critical Path Institute (C-Path) are proud to announce their collaboration to significantly improve the scientific community's ...
Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation...
Diamyd Medical announced earlier this week that the diabetes vaccine Diamyd® has demonstrated significant effect in a subgroup which covers about...
Diamyd Medical today announced the topline results from the placebo-controlled Phase IIb trial DIAGNODE-2, where the diabetes vaccine Diamyd®...
Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) has published results from a meta study that demonstrates a...
Developing therapies for type 1 diabetes Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. Further...
The initial safety and dose escalation part of the Phase I/II trial ReGenerate-1 with Remygen® in individuals with long-term type 1 diabetes today...
The patent now granted by the Japan Patent Office is valid until 2035. Diamyd Medical recently announced the grant of the corresponding patent in...
A new manufacturing facility is being set up in Umeå by Diamyd Medical. The first priority of the new site is to receive the process technology for...
Diamyd Medical announced today, when all 12 patients have been followed throughout the 30-month period in the open-label trial DIAGNODE-1, that the...
Diamyd Medical announces that a new analysis based on data from more than 530 individual patients from previous phase III and II trials in Europe and ...
The agreement with the Norwegian University of Science and Technology in Trondheim (NTNU) refers to a first, investigator initiated clinical Phase II ...
A feasibility study performed as a Master Thesis at Uppsala University and supervised by Diamyd Medical, supports the use of ultrasound guided...
The first seven patients that have now been followed for the entire 30-month period in DIAGNODE-1 continue to show a positive clinical course and are ...
The approval by the Swedish MPA entails that ReGenerate-1, with Diamyd Medical's GABA-based investigational drug Remygen®, will be expanded from the...
With experience from clinical trials in more than 1,000 patients with the diabetes vaccine Diamyd®, preparations for a Conditional Marketing...
During 1 to 30 November 2018, holders of warrants of series TO 1 B and TO 2 A of Diamyd Medical AB have been able to subscribe for shares through...
New results of intralymphatic treatment with the diabetes vaccine Diamyd® indicate the induction of a long-term immune response that supports the...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.